A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant pseudomonas aeruginosa

American Journal of Ophthalmology

Volumn 138, Issue 2, 2004, Pages 226-230

  Rhee, Michelle K ^a,c   Kowalski, Regis P ^a   Romanowski, Eric G ^a   Mah, Francis S ^a   Ritterband, David C ^b   Gordon, Y Jerold ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b NEW YORK EYE AND EAR INFIRMARY   (United States)

^c 310 East 1410003 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFTAZIDIME; CIPROFLOXACIN; GATIFLOXACIN; GENTAMICIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TICARCILLIN; TOBRAMYCIN;

ANIMAL EXPERIMENT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COUNT; BACTERIUM COLONY; BACTERIUM ISOLATE; COMPARATIVE STUDY; CONTROLLED STUDY; EVALUATION; EXPERIMENTAL INFECTION; GRAM NEGATIVE INFECTION; INFECTION RESISTANCE; INFECTION SENSITIVITY; KERATITIS; MICROBIAL SENSITIVITY TEST; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RABBIT;

ANIMALS; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; COLONY COUNT, MICROBIAL; CORNEA; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; EYE INFECTIONS, BACTERIAL; KERATITIS; MICROBIAL SENSITIVITY TESTS; OPHTHALMIC SOLUTIONS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RABBITS;

EID: 3843067692     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2004.03.016     Document Type: Article

References (33)

1. Cohen E.J., Laibson P.R., Arentsen J.J., Clemons C.S. Corneal ulcers associated with cosmetic extended wear soft contact lenses. Ophthalmology. 94:1987;109-114
2. Asbell P., Stenson S. Ulcerative keratitis. Survey of 30 years' laboratory experience. Arch Ophthalmol. 100:1982;77-80
3. Kowalski R.P., Pandya A.N., Karenchak L.M., et al. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonoas aeruginosa. Ophthalmology. 108:2001;1826-1829
4. Guzek J.P., Chacko D., Kettering J.D., Wessels I.F., Aprecio R.M. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of experimental Pseudomonas aeruginosa keratitis. Cornea. 13:1994;500-504
5. Hyndiuk R.A., Eiferman R.A., Caldwell D.R., et al. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. Ophthalmology. 103:1996;1854-1862
6. Alexandrakis G., Alfonso E.C., Miller D. Shifting trends in bacterial keratitis in South Florida and emerging resistance to fluoroquinolones. Ophthalmology. 107:2000;1497-1502
7. Wilhelmus K.R., Hyndiuk R.A., Caldwell D.R., Abshire R.L., Folkens A.T., Godio L.B. 0.3% ciprofloxacin ophthalmic ointment in the treatment of bacterial keratitis. Arch Ophthalmol. 111:1993;1210-1218
8. Chaudhry N.A., Tabandeh H., Rosenfeld P.J., Miller D., Davis J. Scleral buckle infection with ciprofloxacin-resistant Pseudomonas aeruginosa. Arch Ophthalmol. 116:1998;1251
9. Garg P., Sharma S., Rao G.N. Ciprofloxacin-resistant Pseudomonas keratitis. Ophthalmology. 106:1999;1319-1323
10. Chaudhry N.A., Flynn H.W., Murray T.G., Tabandeh H., Mello M.O., Miller D. Emerging ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol. 128:1999;509-510
11. Goldstein M.H., Kowalski R.P., Gordon Y.J. Emerging fluoroquinolone resistance in bacterial keratitis. A 5-year review. Ophthalmology. 106:1999;1313-1318
12. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobials susceptibility tests for bacteria that grow aerobically. Volume 20 (4th ed.), National Committee for Clinical Laboratory Standards, Villanova, Pensylvania (2000) Approved standard (document M7-A5)
13. Kowalski R.P., Romanowski E.G., Yates K.A., Gordon Y.J. Lomefloxacin is an effective treatment of experimental bacterial keratitis. Cornea. 20:2001;306-308
14. Arffa R.C. Infectious ulcerative keratitis: bacterial. Arffa R.C. Grayson's diseases of the cornea. 2nd edition:1991;174-175 C.V. Mosby, St. Louis
15. Wilhelmus KR. Bacterial keratitis. In: Pepose JS, Holland GN, Wilhelmus KR, editors. Ocular Infection & Immunity. St. Louis: C.V. Mosby, 1996:970-1032
16. Reidy J.J., Hobden J.A., Hill J.M., Forman K., O'Callaghan R.J. The efficacy of topical ciprofloxacin and norfloxacin in the treatment of experimental Pseudomonas keratitis. Cornea. 10:1991;25-28
17. Lauffenburger M.D., Cohen K.L. Topical ciprofloxacin versus fortified antibiotics in rabbit models of Staphylococcus and Pseudomonas keratitis. Cornea. 12:1993;517-521
18. Engel L.S., Callegan M.C., Hobden J.A., Reidy J.J., Hill J.M., O'Callaghan R.J. Effectiveness of specific antibiotic/steroid combinations for therapy of experimental Pseudomonas aeruginosa keratitis. Curr Eye Res. 14:1995;229-234
19. Gritz D.V., McDonnell P.J., Lee T.Y., Tang-Liu D., Hubbard B.B., Gwon A. Topical ofloxacin in the treatment of Pseudomonas keratitis in a rabbit model. Cornea. 11:1992;143-147
20. O'Brien T.P., Maguire M.G., Fink N.E., Alfonso E., McDonnell P. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy of bacterial keratitis. Report from the Bacterial Keratitis Study Research Group. Arch Ophthalmol. 113:1995;1257-1265
21. Khokhar S., Sindhu N., Mirdha B.R. Comparison of topical 0.3% ofloxacin to fortified tobramycin-cefazolin in the therapy of bacterial keratitis. Infection. 28:2000;149-152
22. Ball P. Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa and Staphylococcus aureus clinical significance and therapeutic approaches. J Antimicrob Chemother. 26:1990;165-179
23. Coronado V.G., Edwards J.R., Culver D.H., Gaynes R.P. Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States. Infect Control Hosp Epidemiol. 16:1995;71-75
24. Andriole C.L., Andriole V.T. Are all quinolones created equal? Mediguide Infect Dis. 21:2002;1-5
25. Beyer R., Pestova E., Millichap J.J., Stosor V., Noskin G.A., Peterson L.R. A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux. Antimicrob Agents Chemother. 44:2000;798-801
26. Peterson L.R. Quinolone molecular structure-activity relationships what we have learned about improving antimicrobial activity. Clin Infect Dis. 33:(suppl):2001;S180-186
27. Mather R., Karenchak L.M., Romanowski E.G., Kowalski R.P. Fourth generation fluoroquinolones new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 133:2002;463-466
28. Kowalski R.P., Dhaliwal D.K., Karenchak L.M., et al. Gatifloxacin and moxifloxacin an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 136:2003;500-505
29. Giamarellos-Bourboulis E.J., Grecka P., Giamarellou H. Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multiresistant Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 29:1997;81-86
30. Solberg C.O., Sjursen H. Safety and efficacy of meropenem in patients with septicaemia a randomized comparison with ceftazidime, alone or combined with amikacin. J Antimicrob Chemother. 36:1995;157-166
31. Le Thomas I., Couetdic G., Clermont O., Brahimi N., Plesiat P., Bingen E. In vivo selection of a target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy. J Antimicrob Chemother. 48:2001;553-555
32. Fish D.N., Choi M.K., Jung R. Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. J Antimicrob Chemother. 50:2002;1045-1049
33. Lang B.J., Aaron S.D., Ferris W., Hebert P.C., MacDonald N.E. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med. 162:2000;2241-2245